journal article·2021-12Open access

Mimosine functionalized gold nanoparticles (Mimo-AuNPs) suppress β-amyloid aggregation and neuronal toxicity

Bibin G. Anand, Qi Wu, Govindarajan Karthivashan, Kiran P. Shejale, Sara Amidian, Holger Wille, Satyabrata Kar

Bioactive Materials· Volume 6· Issue 12

Abstract

Evidence suggests that increased level/aggregation of beta-amyloid (Aβ) peptides initiate neurodegeneration and subsequent development of Alzheimer's disease (AD). At present, there is no effective treatment for AD. In this study, we reported the effects of gold nanoparticles surface-functionalized with a plant-based amino acid mimosine (Mimo-AuNPs), which is found to cross the blood-brain barrier, on the Aβ fibrillization process and toxicity. Thioflavin T kinetic assays, fluorescence imaging and electron microscopy data showed that Mimo-AuNPs were able to suppress the spontaneous and seed-induced Aβ1-42 aggregation. Spectroscopic studies, molecular docking and biochemical analyses further revealed that Mimo-AuNPs stabilize Aβ1-42 to remain in its monomeric state by interacting with the hydrophobic domain of Aβ1-42 (i.e., Lys16 to Ala21) there by preventing a conformational shift towards the β-sheet structure. Additionally, Mimo-AuNPs were found to trigger the disassembly of matured Aβ1-42 fibers and increased neuronal viability by reducing phosphorylation of tau protein and the production of oxyradicals. Collectively, these results reveal that the surface-functionalization of gold nanoparticles with mimosine can attenuate Aβ fibrillization and neuronal toxicity. Thus, we propose Mimo-AuNPs may be used as a potential treatment strategy towards AD-related pathologies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Alzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Computational Drug Discovery Methods

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (79)

Show source-provided references
1. The amyloid hypothesis of Alzheimer's disease at 25 years10.15252/emmm.201606210 ↗
2. Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric abeta and tau species10.3389/fnins.2019.00659 ↗
3. Neuropathology of Alzheimer's disease10.1002/msj.20157 ↗
4. A Greek tragedy: the growing complexity of alzheimer amyloid precursor protein proteolysis10.1074/jbc.R116.746032 ↗
5. Toward a molecular theory of early and late events in monomer to amyloid fibril formation10.1146/annurev-physchem-032210-103526 ↗
6. An integrated strategy to correlate aggregation state, structure and toxicity of Ass 1-42 oligomers10.1016/j.talanta.2018.05.062 ↗
7. Amyloid beta: structure, biology and structure-based therapeutic development10.1038/aps.2017.28 ↗
8. Towards an understanding of amyloid-beta oligomers: characterization, toxicity mechanisms, and inhibitors10.1039/C6CS00731G ↗
9. Phosphorylation of amyloid beta (Abeta) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease10.18632/aging.100362 ↗
10. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?10.1016/0092-8674(93)90635-4 ↗
11. Advances in Alzheimer's diagnosis and therapy: the implications of nanotechnology10.1016/j.tibtech.2017.06.002 ↗
12. Advances in developing novel therapeutic strategies for Alzheimer's disease10.1186/s13024-018-0299-8 ↗
13. Nanomedicine in Alzheimer's disease: amyloid beta targeting strategy10.1016/bs.pbr.2019.03.001 ↗
14. The chemistry and biological activities of mimosine: a review10.1002/ptr.5636 ↗
15. Potential therapeutic applications of some antinutritional plant secondary metabolites10.1021/jf021150r ↗
16. A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation10.1007/s10495-007-0156-7 ↗
17. G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis10.1523/JNEUROSCI.17-04-01256.1997 ↗
18. Zaman · J. Neurosci. · 1999 · 19 · 982110.1523/JNEUROSCI.19-22-09821.1999 ↗
19. Capsaicin-coated silver nanoparticles inhibit amyloid fibril formation of serum albumin10.1021/acs.biochem.6b00418 ↗
20. Uniform, polycrystalline, and thermostable piperine-coated gold nanoparticles to target insulin fibril assembly10.1021/acsbiomaterials.7b00030 ↗
21. Amyloid fibrils from muscle myoglobin10.1038/35065514 ↗
22. Amyloid formation by globular proteins under native conditions10.1038/nchembio.131 ↗
23. Self-assembly of artificial sweetener aspartame yields amyloid-like cytotoxic nanostructures10.1021/acsnano.9b02284 ↗
24. Tyrosine-generated nanostructures initiate amyloid cross-seeding in proteins leading to a lethal aggregation trap10.1021/acs.biochem.8b00472 ↗
25. Engineered polymer nanoparticles containing hydrophobic dipeptide for inhibition of amyloid-beta fibrillation10.1021/bm3011177 ↗
26. The size-effect of gold nanoparticles and nanoclusters in the inhibition of amyloid-beta fibrillation10.1039/C7NR00699C ↗
27. Progress and perspectives on targeting nanoparticles for brain drug delivery10.1016/j.apsb.2016.05.013 ↗
28. Gold-nanoparticle-based multifunctional amyloid-beta inhibitor against Alzheimer's disease10.1002/chem.201404562 ↗
29. Design of a molecular hybrid of dual peptide inhibitors coupled on AuNPs for enhanced inhibition of amyloid beta-protein aggregation and cytotoxicity10.1002/smll.201601666 ↗
30. Strategically designed antifibrotic gold nanoparticles to prevent collagen fibril formation10.1021/acs.langmuir.7b01504 ↗
31. Prenatal exposure to benzophenone-3 impairs autophagy, disrupts RXRs/PPARgamma signaling, and alters epigenetic and post-translational statuses in brain neurons10.1007/s12035-018-1401-5 ↗
32. The effects of N-terminal mutations on beta-amyloid peptide aggregation and toxicity10.1016/j.neuroscience.2018.03.014 ↗
33. Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated10.1016/j.jmb.2010.06.023 ↗
34. Myricetin inhibits amyloid fibril formation of globular proteins by stabilizing the native structures10.1016/j.colsurfb.2019.110640 ↗
35. Zeta-potential measurement using the Smoluchowski equation and the slope of the current-time relationship in electroosmotic flow10.1016/S0021-9797(03)00142-5 ↗
36. Intrinsic property of phenylalanine to trigger protein aggregation and hemolysis has a direct relevance to phenylketonuria10.1038/s41598-017-10911-z ↗
37. Extrinsic fluorescent dyes as tools for protein characterization10.1007/s11095-007-9516-9 ↗
38. Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro10.1523/JNEUROSCI.2561-13.2013 ↗
39. Small-molecule library screening by docking with PyRx10.1007/978-1-4939-2269-7_19 ↗
40. The protein data bank10.1093/nar/28.1.235 ↗
41. Evidence of rapid coaggregation of globular proteins during amyloid formation10.1021/bi501333q ↗
42. Role of cathepsin D in U18666A-induced neuronal cell death: potential implication in Niemann-Pick type C disease pathogenesis10.1074/jbc.M112.412460 ↗
43. Stronger activation of SREBP-1a by nucleus-localized HBx10.1016/j.bbrc.2015.03.069 ↗
44. The role of PTEN - HCV core interaction in hepatitis C virus replication10.1038/s41598-017-03052-w ↗
45. Corrosion protective properties of epoxy coating containing tetraaniline modified nano-α-Fe2O310.1016/j.porgcoat.2019.04.010 ↗
46. Understanding the self-assembly of Fmoc-phenylalanine to hydrogel formation10.1039/C5SM00843C ↗
47. Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid beta-protein fibrillation and cytotoxicity10.1021/acsami.5b00915 ↗
48. Molecular mechanism of Thioflavin-T binding to amyloid fibrils
49. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide10.1038/nrm2101 ↗
50. Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns10.1039/C7RA05300B ↗
51. Pathogenic effects of D23N Iowa mutant amyloid beta -protein10.1074/jbc.M104135200 ↗
52. Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading10.1002/jcc.21334 ↗
53. Seed-induced acceleration of amyloid-beta mediated neurotoxicity in vivo10.1038/s41467-017-00579-4 ↗
54. Monomer-dependent secondary nucleation in amyloid formation10.1007/s12551-017-0289-z ↗
55. Amyloid toxicity in Alzheimer's disease10.1515/revneuro-2017-0063 ↗
56. Biophysical effect of amino acids on the prevention of protein aggregation10.1093/oxfordjournals.jbchem.a003261 ↗
57. Influence of gold nanoparticles on the kinetics of alpha-synuclein aggregation10.1021/nl403490e ↗
58. Rationally designed peptidomimetic modulators of abeta toxicity in Alzheimer's disease10.1038/srep08139 ↗
59. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds10.3390/ijms140612411 ↗
60. Spectroscopic studies on the interaction of mimosine with BSA and DNA10.1016/j.molstruc.2018.01.039 ↗
61. Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization10.1074/jbc.M204168200 ↗
62. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils10.1038/nsmb.1799 ↗
63. Identification of key regions and residues controlling Abeta folding and assembly10.1038/s41598-017-10845-6 ↗
64. Fibril structure of amyloid-beta(1-42) by cryo-electron microscopy10.1126/science.aao2825 ↗
65. Polyproline chains destabilize the Alzheimer's amyloid-beta protofibrils: a molecular dynamics simulation study10.1016/j.jmgm.2019.107456 ↗
66. Kinetic studies of inhibition of the amyloid beta (1-42) aggregation using a ferrocene-tagged beta-sheet breaker peptide10.1016/j.ab.2012.11.025 ↗
67. The role of phenolic OH groups of flavonoid compounds with H-bond formation ability to suppress amyloid mature fibrils by destabilizing beta-sheet conformation of monomeric Abeta17-4210.1371/journal.pone.0199541 ↗
68. Natural compounds for Alzheimer's disease therapy: a systematic review of preclinical and clinical studies10.3390/ijms20092313 ↗
69. Secondary metabolites from plants possessing inhibitory properties against beta-amyloid aggregation as revealed by thioflavin-T assay and correlations with investigations on transgenic mouse models of Alzheimer's disease10.3390/biom10060870 ↗
70. Curcumin attenuates amyloid-beta aggregate toxicity and modulates amyloid-beta aggregation pathway10.1021/acschemneuro.5b00214 ↗
71. Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers10.1038/nchembio.624 ↗
72. Nanotherapeutics for Alzheimer's disease (AD): past, present and future10.3109/1061186X.2011.607499 ↗
73. Decreasing amyloid toxicity through an increased rate of aggregation10.1039/C6CP06765D ↗
74. Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice10.2353/ajpath.2009.081096 ↗
75. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo10.1002/jnr.22640 ↗
76. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease10.1006/nbdi.2000.0364 ↗
77. Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: from preclinical to translational studies10.1016/j.biomaterials.2019.119704 ↗
78. Key for crossing the BBB with nanoparticles: the rational design10.3762/bjnano.11.72 ↗
79. Advancements in the blood-brain barrier penetrating nanoplatforms for brain related disease diagnostics and therapeutic applications10.3390/polym12123055 ↗